POSC77 Incorporating Possibility of Cure into Cost Utility Analysis for Nivolumab in Adjuvant Treatment of Resected Stage III/IV Melanoma in France

Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.482
https://www.valueinhealthjournal.com/article/S1098-3015(21)02277-4/fulltext
Title : POSC77 Incorporating Possibility of Cure into Cost Utility Analysis for Nivolumab in Adjuvant Treatment of Resected Stage III/IV Melanoma in France
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02277-4&doi=10.1016/j.jval.2021.11.482
First page :
Section Title :
Open access? : No
Section Order : 10017
Categories :
Tags :
Regions :
ViH Article Tags :